Drew Moghanaki, Professor, Chief of Thoracic Oncology at the Department of Radiation Oncology and Stanley Iezman and Nancy Stark Endowed Chair in Thoracic Radiation Oncology Research at David Geffen School of Medicine at UCLA, and Chief Medical Officer of Respirati, shared a post on X:
“Today was the first time I observed Salma Jabbour in a debate.
It wouldn’t have mattered who was on the other side as she was absolutely spectacular using data and logic to clarify CRT is often the better local therapy for bulky T4N2 NSCLC. 
She also referenced a few guidelines to clarify why it’s a risky proposition to attempt surgery in these patients.”
Definitive Radiotherapy to the Primary Tumor in Stage IV NSCLC: What the New IASLC Consensus Means
